Research programme: anti-cancer therapeutics - Proteros biostructures/Janssen

Alternative Names: Covalent Flt3-Cys828 inhibitors - Proteros biostructures; Fms like tyrosine kinase 3 inhibitors - Proteros biostructures

Latest Information Update: 03 Aug 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Proteros Biostructures
Developer Janssen; Proteros Biostructures
Class Antineoplastics; Small molecules
Mechanism of Action Fms-like tyrosine kinase 3 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Acute myeloid leukaemia
Research Cancer

Most Recent Events

27 Jul 2017 Proteros biostructures and Janssen Biotech enter into a research collaboration for developing cancer therapeutics against epigenetic targets
03 Jun 2016 Preclinical trials in Acute myeloid leukaemia (Flt3 mutant) in Germany (unspecified route)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.